There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...